Infant Bacterial Therapeutics has today, September 8, 2017, hosted a Capital Markets Day for investors, financial analysts and media in Stockholm. The...
Message from the CEO IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations...
Message from the CEO IBTs operations will during the current year be focused on completion of the ongoing Phase ll study and planning of the following...
Infant Bacterial Therapeutics AB (publ) Annual Report 2016 is now available on the companies website www.ibtherapeutics.com. A physical copy of the Annual...
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting at 2:00 p.m. on Thursday, 4 May 2017, at Citykonferensen Ingenjörshuset...
Infant Bacterial Therapeutics AB (publ) ("IBT"), today traded on Nasdaq First North, has applied and been approved for listing on Nasdaq First...
Infant Bacterial Therapeutics AB (publ) ("IBT"), a pharmaceutical company that develops drugs that meet the medical needs of premature infants...
Message from the CEO "During the month of June, the first patients were recruited and dosed in IBTs clinical study, IBP-9414, in the USA. The last...
Infant Bacterial Therapeutics AB (publ) ("IBT") announces that the last premature infant has now been enrolled and recruitment to the Phase 2...
Infant Bacterial Therapeutics AB (publ) ("IBT"), a pharmaceutical company that develops drugs that meet the medical needs of premature infants...

Subscribe to our press releases